Atricure Inc (ATRC) 15.20 $ATRC AtriCure Announces the

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2016 at 4:15 AM

Atricure Inc (ATRC) 15.20 $ATRC

AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
BusinessWire - Tue Jun 21, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.
ATRC: 15.20 (+0.20)

AtriCure to Present at the UBS Global Healthcare Conference
BusinessWire - Mon May 02, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.20 (+0.20)

AtriCure Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
--U.S. sales of $28.3 million - up 23.3%
ATRC: 15.20 (+0.20)

AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
BusinessWire - Thu Apr 28, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit.
ATRC: 15.20 (+0.20)

AtriCure Receives FDA Clearance for New AtriClip(R) Device
BusinessWire - Tue Apr 26, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.
ATRC: 15.20 (+0.20)

New Strong Buy Stocks for April 19th
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BMA: 75.16 (+0.58), BV: 4.20 (-0.04), ANCX: 19.65 (+0.27), MTGE: 15.62 (-0.09), ATRC: 15.20 (+0.20)

What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 15.66 (+0.33), ATRC: 15.20 (+0.20)

AtriCure Announces 510(k) Clearance for the cryoFORM(TM) Cryoablation Probe
BusinessWire - Tue Apr 12, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.
ATRC: 15.20 (+0.20)

AtriCure to Announce First Quarter 2016 Financial Results
BusinessWire - Tue Apr 05, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016.
ATRC: 15.20 (+0.20)

New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 21.28 (+0.86), BXE: 1.05 (+0.06), BKCC: 7.99 (+0.08), AKAO: 3.84 (-0.05), ATRC: 15.20 (+0.20)

New Strong Buy Stocks for March 21st
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 9:04AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BV: 4.20 (-0.04), ESIO: 6.03 (+0.21), CIDM: 1.09 (+0.07), ATRC: 15.20 (+0.20), CGNT: 1.06 (+0.01)

Phibro Animal Health (PAHC) in Focus: Stock Jumps 5.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 7:35AM CDT
Phibro Animal Health Corporation (PAHC) was a big mover last session, as the company saw its shares rise over 5% on the day.
PAHC: 19.88 (+0.25), ATRC: 15.20 (+0.20)

Shares of ATRC Down 16.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 07, 9:32AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 2 months, AtriCure has returned 16.36% as of today's recent price of $16.79.
ATRC: 15.20 (+0.20)

New Strong Buy Stocks for March 3rd
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 9:04AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
APEI: 28.63 (+0.83), MTGE: 15.62 (-0.09), AMCX: 59.35 (+0.58), ARQL: 1.74 (+0.08), ATRC: 15.20 (+0.20)

AtriCure Down 19.0% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Tue Feb 09, 10:17AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 1 month, AtriCure has returned 19.00% as of today's recent price of $16.26.
ATRC: 15.20 (+0.20)

AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Feb 01, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016.
ATRC: 15.20 (+0.20)

Downtrend Call Working As AtriCure Stock Falls 16.6% (ATRC)
Comtex SmarTrend(R) - Fri Jan 29, 10:48AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 3 weeks, AtriCure has returned 16.56% as of today's recent price of $16.75.
ATRC: 15.20 (+0.20)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mountain Living: Facing the Population Growth Crunch

Population Growth Reshaping U.S. Mountain Communities Living in a picturesque mountain town used to offer an idyllic escape from the hustle and bustle of city life. But now, even these scenic enclaves are feeling the squeeze from a wave of population growth that's hard to ignore. Mark Cromer tackles this head-on in his new Forum paper, 'The Long Goodnight of Rocky...

Compounded Meds: A Tailored Approach to Health Needs

Custom Compounding: A Lifeline for Specific Needs Standard meds can sometimes feel like a one-size-fits-all shirt—sure it fits, but not comfortably for everyone. Enter the world of custom-compounded medications, where pharmacists like Laura Temple in Azle, Texas, create tailor-made solutions for patients. Think of it as fine-tuning the exact gear needed to climb that...

Expert Vet Advice: When Pet Surgery Is Necessary

Tough Calls: Knowing When Your Pet Needs Surgery Alright, when it comes to our furry companions, knowing when to opt for surgery ain't no walk in the park. It's a tricky balance, folks. Is that lump something to worry about? Will that limp heal on its own? HelloNation's recent piece dives into these questions, leveraging the expertise of Veterinarian Lorrie Riggs from...

Mario Lopez: Homegrown Star Hosts Birthday Tequila Bash

Not every day do you get a celeb hitting their home turf just to throwback with fans, but that's Mario Lopez for you. Coming right into San Diego for his birthday month, Lopez isn't just sipping tequila—he’s signing it. Swing by Old Town Tequila and Keg N Bottle this October 24 if you want a bottle of Casa México Tequila adorned with a little star power. Sips,...

Amcor's Q3 2026 Results Loom: What's at Stake?

Anticipation Builds for Amcor's Q3 2026 Financials Well, here we are again, staring down the barrel of another quarterly earnings report from Amcor plc (NYSE: AMCR). They've circled November 4th, 2026, in red on their calendars to dish out the numbers after the U.S. market's last bell rings. Investors, analysts, and the peanut gallery will be tuning in, and why not? At a...

American Lung Association Tackles Indoor Pollution

The Unseen Threat Lurking Indoors When you think about air pollution, your mind probably jumps to smog-choked city streets. But, surprise! The air inside your cozy living room could actually be pulling a fast one on you, being two to five times filthier than what’s outside. Now, that’s a hair-raising thought. A Closer Look at Indoor Air Hazards Folks don’t usually...

b.well and MyDirectives Streamline Access to Care Plans

Pioneering Access to Critical Care Documents Ever thought about where all those critical healthcare documents are stashed? Trust me, it’s often a mess—file cabinets, bookshelves, or stuck in some forgotten safety deposit box. Well, b.well Connected Health and MyDirectives are rolling up their sleeves to change that. They've teamed up to make advance care planning...

WF Holding Cancels Additional Purchase Rights in Deal

WF Holding Calls Off Extra Purchase Rights Well, someone's decided to hit the brakes over at WF Holding Limited (NASDAQ:WFF). They're pulling the plug on an extra purchase gravy train they’d previously left open for investors. Straight from Kuala Lumpur, WF Holding's been in the fiberglass plastic game for over three decades, pushing out a product line that's almost as...

Longitude Health Strengthens Ranks with Chris Shea Hire

New Leadership for Longitude Health's Legal Team Longitude Health's recent appointment of Chris Shea as Chief Legal and Administrative Officer might not make immediate waves in stock circles, but if you've been paying attention to healthcare's convoluted growth dance, you'd see the stakes. Shea's been knee-deep in the nitty-gritty of the health system labyrinth for more...

Ping An's Brain Health Program Takes Bold Steps Forward

New Moves in Neural Care: Ping An's Pioneering Path Grasping headlines with a forward-thinking initiative, Ping An Insurance (Group) Company of China just cracked open the book on a fresh chapter in senior healthcare. October 21st witnessed the grand unveiling of China's first Brain Health Service Management Program in Beijing. Tailored like a smart suit for Alzheimer's...